What thymulin is
Thymulin is a nonapeptide hormone made by thymic epithelial cells, with the sequence pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn. Jean-Francois Bach's group in Paris isolated it from pig and human serum in the early 1970s and called it facteur thymique serique, or serum thymic factor (FTS). Mireille Dardenne and colleagues renamed it thymulin in 1981, after showing that the peptide chain alone has no measurable biological activity. It needs a zinc ion bound to it first (Bach and Dardenne, Med Oncol Tumor Pharmacother, 1989).
Mechanism: a hormone that only works with zinc attached
Thymulin binds zinc in a 1:1 molar ratio. Nuclear magnetic resonance studies show the metal ion locks the peptide into the three-dimensional shape its receptor requires (Dardenne and Pleau, Met Based Drugs, 1994). Strip the zinc away and the remaining apopeptide, sometimes labeled apo-FTS, is essentially inert. Few peptide hormones have a trace mineral working this directly as an on/off switch rather than a supporting cofactor.
Once zinc-bound, thymulin drives T-cell differentiation in the thymus and periphery, raises natural killer cell activity, and corrects skewed helper-to-suppressor T-cell ratios in models of immune deficiency. Serum thymulin activity tracks zinc intake closely enough that researchers use it as a functional readout of zinc status rather than measuring the metal on its own (Prasad et al., J Clin Invest, 1988).
Thymulin research: what the studies show
The clearest human data come from zinc-deficiency work. Prasad and colleagues studied two volunteers with experimentally induced mild zinc deficiency alongside six sickle cell anemia patients and six matched controls. Thymulin activity fell with zinc depletion in every group, along with a lower CD4/CD8 ratio and reduced interleukin-2 output, and zinc repletion reversed both the immune changes and the drop in thymulin (Prasad et al., J Clin Invest, 1988).
A larger clinical test came out of gastroenterology. Brignola and colleagues gave 27 Crohn's disease patients with low baseline zinc either 60 mg or 200 mg of zinc sulfate per day, or placebo, for three months. Plasma zinc and thymulin activity rose significantly only in the 200 mg group, not at the lower dose or on placebo (Brignola et al., Aliment Pharmacol Ther, 1993, n=27). The dose-response pattern argues against a coincidental correlation and toward zinc genuinely driving the hormone's output.
Autoimmune disease research has centered on rheumatoid arthritis. Amor and colleagues ran two randomized, double-blind, placebo-controlled trials of a synthetic thymulin variant called nonathymulin, dosed at 1, 5, and 10 mg per day. The 5 mg arm produced clinical improvement in 56% of patients against 17% on placebo (p<0.02) across four objective disease-activity measures, though the trials found no clear matching shift in the immunological markers the researchers expected to move alongside the clinical response (Amor et al., Ann Rheum Dis, 1987). An earlier open-label study incubated synthetic FTS-Zn with lymphocytes from nine rheumatoid arthritis patients and found the abnormal helper-to-suppressor ratio corrected in eight of the nine samples tested (Faure et al., Clin Exp Rheumatol, 1987, n=9).
A thymulin-derived fragment called PAT, short for peptide analogue of thymulin, has separately been tested for anti-inflammatory and analgesic effects that appear independent of zinc chemistry. In a rat model of carrageenan-induced inflammation, pretreatment with PAT at 1, 5, or 25 micrograms reduced mechanical and thermal hyperalgesia in a dose-dependent pattern, with potency comparable to dexamethasone and indomethacin, and lowered local IL-1beta, IL-6, TNF-alpha, and nerve growth factor concentrations at the injection site (Safieh-Garabedian et al., Br J Pharmacol, 2002).
Aging research adds a fourth angle. Thymulin output falls with age as the thymus involutes, and in 22-month-old mice, one month of zinc supplementation reversed much of that decline: the thymus regrew, natural killer cell activity recovered, and mitogen responsiveness moved back toward young-adult levels (Mocchegiani et al., Int J Immunopharmacol, 1995). The authors attributed the effect to restoring the animals' zinc pool rather than to any independent pharmacological action of zinc, which fits the wider pattern in this literature: thymulin behaves as much like an indicator of zinc sufficiency as an autonomous hormone.
What is missing is a modern, adequately powered human trial against a hard clinical endpoint. Most of the foundational work above is 30 to 45 years old, run in small cohorts, and predates the trial-design standards used today. The mechanism is well characterized. The human evidence base is not current.
Practical considerations for research handling
Thymulin ships lyophilized and gets reconstituted with bacteriostatic water, following the same handling rules used for other small peptides in the catalog. The reconstitution guide covers gentle mixing and target-concentration math. Because the human trials cited above used exact milligram-per-day dosing schedules, replicating a published protocol calls for checking concentration and volume with the dosing calculator rather than estimating by eye.
One handling detail is specific to this compound: its activity depends on an intact zinc-peptide complex, not just an intact amino acid chain. A vial that has degraded chemically can still show the correct peptide mass on a purity assay while having lost the zinc-bound, biologically active fraction, since apo-thymulin and zinc-bound thymulin sit close together in molecular weight. A clean HPLC trace is necessary evidence of an intact peptide. It is not sufficient evidence of biological activity.
Storage otherwise follows the rules in the lyophilized peptide storage guide: refrigerate on arrival, limit freeze-thaw cycles, and keep vials out of direct light.
Sourcing thymulin research material in Indonesia
Indonesia's heat and humidity make that storage guidance more than boilerplate. A lyophilized thymulin vial shipped to Bali, Jakarta, or another Indonesian city should go into a refrigerator on arrival rather than sit through a tropical afternoon at ambient temperature, since heat speeds up both general peptide degradation and the separate risk of losing the zinc-bound active fraction. Under BPOM's framework for laboratory and research materials, thymulin supplied for research use is handled as a laboratory reagent, a category distinct from any registered pharmaceutical product.
How thymulin compares to other thymic peptides
Thymulin gets grouped informally with other thymus-derived peptides, but the mechanism differs sharply from the thymosins. Thymosin Alpha-1 signals through toll-like receptors on immune cells and needs no metal cofactor. Thymulin's entire biological activity rides on a bound zinc ion, and the two peptides came out of separate discovery programs decades apart.
The trial record for Thymosin Alpha-1, including its Zadaxin formulation and the mixed results from recent sepsis trials, is covered in the Thymosin Alpha-1 research overview. Both peptides currently sit in the same general section of the peptide catalog, since the shared thymic origin gets the two searched together despite the mechanistic gap between them.